The female nuclear medicine patient is of special concern in evaluating radiation dose and risk in nuclear medicine. The female's overall body size and organ sizes generally are smaller than those of her male counterpart (thus her radiation doses will be higher, given the same amounts of administered activity and similar biokinetics); female gonads are inside the body instead of outside and are near several organs often important as source organs in internal dosimetry (urinary bladder, liver, kidneys, intestines); risk of breast cancer is significantly higher among females than males; and in the case of pregnancy, exposure to radiation of the embryo/fetus and the nursing infant are of special concern in such an analysis. All these concerns are addressed in this study through a comparative study of radiation doses for males and females over a large number (-60) Women's gonad doses, however, may be as much as 10 to 30 times higher than those in men, although 2-to 3-fold differences are common. Many radiopharmaceuticals are administered to women of childbearing age; however, little is known about how much activity crosses the placenta and about the biokinetics in the fetus should it occur. Nonetheless, dose estimates are provided at four stages of pregnancy (early, 3-month, 6-month, and 9-month gestation) for a large number of radiopharmaceuticals, whether or not quantitative estimates of placental crossover can be made. Many radiopharmaceuticals are also excreted in breast milk of nursing mothers. Breast feeding interruption schedules are suggested through analysis of the observed kinetics of these pharmaceuticals and an assumed dose limit of 1 mSv (effective dose equivalent) to the infant.
Introduction
The risk-benefit analysis for patients in exposure. However, the female nuclear nuclear medicine necessarily uses calculated medicine patient is of special concern to estimates of radiation doses (absorbed dose, the evaluation of radiation dose and risk in dose equivalent, effective dose, etc.) for nuclear medicine. The female's overall exposed persons. Analysis is different than body size and organ sizes are generally that used in other situations, as the person smaller than those of her male counterpart receiving the radiation dose usually is also (thus her radiation doses will be higher, the one who directly benefits from the given the same amounts of administered activity and similar biokinetics); female gonads are inside the body instead of outside and are near several organs often important as source organs in internal dosimetry (urinary bladder, liver, kidneys, intestines); risk of breast cancer is significantly higher among females than males; and in the case of pregnancy, exposure of the embryo/fetus and the nursing infant is of special concern in such an analysis. This study analyzes the differences in organ doses and effective doses [as defined in International Commission on Radiological Protection 60 (ICRP 60) (1)], and gonad doses between male and female nuclear medicine patients. Radiation dose estimates for many nuclear medicine procedures involving a wide variety of radionuclides and pharmaceuticals (even some that are no longer in common use, in order to broaden the spectrum of observed results) were developed for standard adult males (70 kg) and females (57 kg), and differences in organ, gonad, and effective doses were studied. Results from several previous studies on radiation dosimetry in pregnancy and lactation were included to provide a more complete discussion ofwomen's health concerns in nuclear medicine.
This study provides only estimates of radiation dose for the adult female from nuclear medicine procedures. This information may be used to analyze risks that women might incur from these procedures and to determine how these risks may differ from those incurred by men; such an analysis is outside the scope of this work. Additional information needed to complete such an analysis would include the amount of activity administered per study, the number of studies performed per Results from two recent studies performed by RIDIC were also included in this study-one on radiation dosimetry for the embryo/fetus for the pregnant nuclear medicine patient and one on the dose to the nursing infant for breast-feeding mothers who received radiopharmaceuticals. Extensive detail on the methods used in these two studies are published elsewhere (7, 8) 6 -month, and 9-month gestation) in the MIRDOSE 3.1 software, (4, 6) . There are many radiopharmaceuticals that can be administered to women of childbearing age for which no informationabout placental crossover could be found in the literature. In these cases, radiation dose estimates to the fetus were developed using only an estimate of the residence times in the mother's organs. It was not thought prudent to just assume values for placental crossover (e.g., 0.5, 1, 5%) with no literature support. These radiation doses, therefore, may underestimate fetal doses in cases in which significant placental crossover occurs, but at present they represent the best estimates available. The dose to the embryo/fetus is thus reported for many radiopharmaceuticals at these four assumed stages of pregnancy. In the study on breast feeding, values reported in the literature for the excretion of many radiopharmaceuticals in the breast milk of nursing mothers participating in nuclear medicine studies were used in a standard model for nursing that assumed the infant consumed 1000 ml/day of milk, feeding at 3-hr intervals, starting either immediately (3 Table 4 is a summary of absorbed doses to the fetus from administration of radiopharmaceuticals to pregnant women (7) . These doses are expressed as absorbed dose to the embryo/fetus per unit activity administered to the mother. Shaded rows in the table indicate that some information was available on placental crossover and was used in the estimates. Table 5 is a summary of the recommendations for possible interruption of breast feeding in the nursing mother given a radiopharmaceutical, given the 1-mSv infant dose criterion. Further details on the dosimetry are given in the USNRC (8) .
Discussion
As seen in Table 2 and in Figures 1 and 3 Fetal doses for most radiopharmaceuticals, when expressed on the basis of dose to the fetus per unit activity administered to the mother, for most radiopharmaceuticals tend to decrease throughout gestation. As the baby grows, the absorbed fractions for the fetus absorbing radiation from maternal organs will increase, but the baby's increase in mass generally offsets this increase (recall that absorbed dose is energy absorbed per unit mass). Exceptions to this occur in cases in which there is a considerable increase in the placental crossover of the radiopharmaceutical as pregnancy progresses, which increases fetal self-dose. Some exceptions also occur for certain organs in the mother's body for which the specific absorbed fraction increases throughout gestation, notably the liver, lungs, and spleen (6) . The doses shown in this report give only the average absorbed dose to the whole fetus; current models do not permit adequate modeling of the dose to individual organs within the fetus, although this may be quite important in many circumstances. Some authors (11, 12) have attempted on an individual basis to make such individual organ dose estimates. The most notable of these inquiries is that of Watson (11) , who demonstrated clearly the importance of the dose to the fetal thyroid for iodine (especially I-131) administration to women after week 10 of gestation.
The dose estimate analysis for the nursing infant reveals that for many radiopharmaceuticals no interruption of breast feeding is indicated, even given the relatively low effective dose decay quickly after administration. Also, because of their short half-lives and their radiation spectrum, most of these nuclides give a fairly low dose per unit intake. A few of the Tc-99m compounds and one I -123 compound required short interruption periods so as not to exceed the 1-mSv effective dose equivalent value. A difference was seen between in vivo-and in vitro-labeled Tc-99m red blood cells, as the former have a higher assumed fraction of free pertechnetate in the injectateTc-99m pertechnetate required a 24-hr interruption to satisfy the dose criterion.
The most important compounds in the analysis were 1-131 NaL, Ga-67 citrate, and Tl-201 chloride. Because of either their long physical or biological half-times or their high radiation dose per unit intake values, or both, these compounds have the potential for relatively high infant doses, and if these studies are used, cessation of breast feeding is probably indicated.
In summary, it is clear that there are special concerns with regard to the female nuclear medicine patient in the risk/benefit analyses. The most important concerns arise when a woman is either pregnant or breast feeding, but the slightly higher organ and gonad radiation burdens a woman carries compared to her male counterpart are also of interest. A logical extension of this work would be to apply the amount of activity administered per study and the number of nuclear medicine studies performed on men and women for each type of study and to examine the population doses identified in routine nuclear medicine practice. Such information was not available at the time of this writing, but this study provides information that could be used for this analysis should it be undertaken.
